Breaking News Instant updates and real-time market news.

EXAS

Exact Sciences

$61.51

-3.2 (-4.95%)

, PFE

Pfizer

$43.23

0.64 (1.50%)

07:19
10/30/18
10/30
07:19
10/30/18
07:19

Exact Sciences weakness a buying opportunity, says UBS

UBS analyst Daniel Brennan previewed Q3 results for Exact Sciences (EXAS) and said his positive thesis is focused on Q4 where he hopes to see a meaningful increase in testing frequency as the result of its strategic relationship with Pfizer (PFE). He views Q3 as less important to his thesis and would view any weakness following the report as a buying opportunity. Brennan reiterated his Buy rating and $100 price target on Exact Sciences shares.

EXAS

Exact Sciences

$61.51

-3.2 (-4.95%)

PFE

Pfizer

$43.23

0.64 (1.50%)

  • 30

    Oct

  • 30

    Oct

  • 07

    Nov

EXAS Exact Sciences
$61.51

-3.2 (-4.95%)

10/10/18
LEER
10/10/18
NO CHANGE
LEER
Outperform
Exact Sciences pullback on Freenome poster a buying opportunity, says Leerink
Leerink analyst Puneet Souda sees a buying opportunity in shares of Exact Sciences, which are reacting negatively to a competitive liquid biopsy CRC screening poster that was presented yesterday by Freenome at the ongoing American College of Gastroenterology conference. While Souda views Freenome's leadership and team as "extremely competent" compared to CellMax, another company seeking to compete with Exact Sciences, Freenome's test is still in developmental stages and commercialization of a such a test "is a long road," Souda tells investors. The analyst, who is also not ruling out the possibility that Exact Sciences is open to reviewing opportunities in liquid biopsy, keeps an Outperform rating on the stock.
10/10/18
ADAM
10/10/18
NO CHANGE
ADAM
Buy
Exact Sciences potential challenger Freenome 'bears watching,' says Canaccord
Canaccord analyst Mark Massaro noted that Freenome, an emerging liquid biopsy company backed by Google Ventures and Andreesen Horowitz, presented early data from its colorectal cancer screening test that it is seeking to develop to compete with Exact Sciences' Cologuard test. While he does not consider Freenome to present any near-term risk to Exact Sciences, he believes that its technology platform bears watching and that it is possible they could launch a blood-based FDA-cleared colon screening test in 2021 or 2022 at the earliest. He maintains a Buy rating on Exact Sciences shares.
10/09/18
UBSW
10/09/18
NO CHANGE
UBSW
UBS initiates coverage of Life Sciences and Diagnostics Tools sector
UBS analyst Daniel Brennan initiated coverage of the Life Sciences and Diagnostics Tools sector. He said demand is accelerating across his universe but valuations are extended. He expects strong fundamentals to continue into 2019 but he said selectivity is the key. In the group, his Buy ratings include Exact Sciences (EXAS), Iqvia (IQV), NanoString (NSTG), Syneos Health (SYNH) and Thermo Fisher (TMO).
10/09/18
UBSW
10/09/18
INITIATION
Target $100
UBSW
Buy
Exact Sciences initiated with a Buy at UBS
UBS analyst Daniel Brennan initiated Exact Sciences with a Buy rating and $100 price target.
PFE Pfizer
$43.23

0.64 (1.50%)

10/25/18
WELS
10/25/18
NO CHANGE
WELS
Wells Fargo says Trump speech today won't be end of drug pricing proposals
Wells Fargo analyst David Maris notes that Politico and other media outlets are reporting that President Donald Trump will propose several new initiatives to address high drug prices when he speaks later today at the U.S. Department of Health and Human Services. Maris thinks Trump's focus will be on how other countries are "freeloading" on U.S. innovation with lower negotiated pricing, stating that news reports make it appear that the administration is targeting the industry for action, rather than other countries to raise their spending. While Maris acknowledges the timing of the speech being near the mid-term elections, he believes these proposals are simply the follow-though of earlier promises. He also expects this is not the end of proposals to address the issue of U.S. drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/23/18
WOLF
10/23/18
INITIATION
Target $46
WOLF
Peer Perform
Pfizer reinitiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Pfizer with a Peer Perform and $46 price target.
10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/08/18
GSCO
10/08/18
NO CHANGE
Target $36
GSCO
Sell
Ionis' Tegsedi to face commercial headwinds, says Goldman Sachs
After the FDA approved Ionis (IONS) and affiliate Akcea Therapeutics' (AKCA) Tegsedi for adult polyneuropathy of hereditary transthyretin-mediated amyloidosis, but with a black box warning, Goldman Sachs analyst Salveen Richter said he believes the drug faces commercial headwinds. He cites the underlying safety profile and requirement for consistent monitoring as well as the recent launch of Alnylam's (ALNY) Onpattro and expected launch of Pfizer's (PFE) tafamidis in the first half of 2019. Richter keeps a Sell rating on Ionis shares with a price target of $36.

TODAY'S FREE FLY STORIES

NET

Cloudflare

$17.96

(0.00%)

, AMZN

Amazon.com

$1,837.49

-6 (-0.33%)

07:40
09/15/19
09/15
07:40
09/15/19
07:40
On The Fly
Opening Day: Cloudflare jumps in market debut »

Shares of Cloudflare…

NET

Cloudflare

$17.96

(0.00%)

AMZN

Amazon.com

$1,837.49

-6 (-0.33%)

MSFT

Microsoft

$137.21

-0.33 (-0.24%)

STSA

Satsuma Pharmaceuticals

$16.61

(0.00%)

SWTX

SpringsWorks Therapeutics

$22.75

(0.00%)

SDC

SmileDirectClub

$18.68

1.8 (10.66%)

TXG

10x Genomics

$53.80

0.85 (1.61%)

PTON

Peloton

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

NVST

Envista

$0.00

(0.00%)

XGN

Exagen

$0.00

(0.00%)

DDOG

Datadog

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

NDAQ

Nasdaq

$99.51

0.5 (0.51%)

DHR

Danaher

$141.02

-0.84 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

  • 17

    Sep

  • 17

    Sep

  • 27

    Oct

  • 07

    Nov

  • 18

    Sep

  • 19

    Sep

  • 26

    Sep

04:55
09/15/19
09/15
04:55
09/15/19
04:55
Conference/Events
SunTrust retail/consumer goods analysts to hold a dinner meeting »

Retail/Consumer Goods…

ABT

Abbott

$84.25

-0.96 (-1.13%)

, ADPT

Adaptive Biotechnologies

$43.28

3.49 (8.77%)

13:22
09/14/19
09/14
13:22
09/14/19
13:22
Conference/Events
William Blair diagnostic products/med tech analyst to hold a group luncheon »

Diagnostic Products &…

ABT

Abbott

$84.25

-0.96 (-1.13%)

ADPT

Adaptive Biotechnologies

$43.28

3.49 (8.77%)

BDX

Becton Dickinson

$260.68

-1.41 (-0.54%)

COO

Cooper Companies

$301.95

-3 (-0.98%)

EXAS

Exact Sciences

$106.72

-1.99 (-1.83%)

GH

Guardant Health

$77.54

0.49 (0.64%)

NEO

NeoGenomics

$21.34

-1.22 (-5.41%)

LMNX

Luminex

$22.62

0.1 (0.44%)

HAE

Haemonetics

$125.55

-0.31 (-0.25%)

STAA

STAAR Surgical

$29.21

0.415 (1.44%)

QGEN

Qiagen

$33.97

-0.105 (-0.31%)

NVTA

Invitae

$21.70

-0.2 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

  • 13

    Nov

  • 05

    Dec

CRTO

Criteo

, TWTR

Twitter

13:19
09/14/19
09/14
13:19
09/14/19
13:19
Conference/Events
FBN Securities Tech/Internet analyst to hold a group luncheon »

Technology & Internet…

CRTO

Criteo

TWTR

Twitter

SNAP

Snap

GOOGL

Alphabet Class A

FB

Facebook

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 17

    Sep

  • 20

    Sep

  • 24

    Sep

  • 27

    Oct

T

AT&T

$37.90

-0.46 (-1.20%)

09:06
09/14/19
09/14
09:06
09/14/19
09:06
Periodicals
AT&T stock already benefiting from activist involvement, Barron's says »

AT&T 's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

DIS

Disney

$138.00

0.44 (0.32%)

, NFLX

Netflix

$294.00

5.08 (1.76%)

09:04
09/14/19
09/14
09:04
09/14/19
09:04
Periodicals
Consumers might not be as in love with Apple TV+ as Wall Street, Barron's says »

Following Apple's…

DIS

Disney

$138.00

0.44 (0.32%)

NFLX

Netflix

$294.00

5.08 (1.76%)

AAPL

Apple

$218.71

-4.4 (-1.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Oct

UAL

United Airlines

$91.37

1.99 (2.23%)

08:58
09/14/19
09/14
08:58
09/14/19
08:58
Periodicals
United Airlines could get boost after short squeeze, Barron's says »

United Airlines stock has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

BAC

Bank of America

$30.12

0.44 (1.48%)

08:55
09/14/19
09/14
08:55
09/14/19
08:55
Periodicals
Bank of America stock worth betting on, Barron's says »

Amid talk of a coming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

TPR

Tapestry

$25.16

-0.43 (-1.68%)

08:49
09/14/19
09/14
08:49
09/14/19
08:49
Periodicals
Coach parent's turnaround could be coming, Barron's says »

Even in a rough year for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UHAL

Amerco

$379.63

4.21 (1.12%)

08:45
09/14/19
09/14
08:45
09/14/19
08:45
Periodicals
U-Haul parent stock 'a better-kept secret,' Barron's says »

Amerco (UHAL), owner of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CP

Canadian Pacific

$228.59

-1.38 (-0.60%)

, CNI

Canadian National

$92.13

-0.31 (-0.34%)

08:41
09/14/19
09/14
08:41
09/14/19
08:41
Periodicals
Railroad stocks struggling as challenges increase, Barron's says »

North American railroads…

CP

Canadian Pacific

$228.59

-1.38 (-0.60%)

CNI

Canadian National

$92.13

-0.31 (-0.34%)

UNP

Union Pacific

$171.49

3.81 (2.27%)

CSX

CSX

$72.50

0.96 (1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

MO

Altria Group

$42.01

-0.77 (-1.80%)

, BTI

British American Tobacco

$36.76

-1.21 (-3.19%)

08:06
09/14/19
09/14
08:06
09/14/19
08:06
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

MO

Altria Group

$42.01

-0.77 (-1.80%)

BTI

British American Tobacco

$36.76

-1.21 (-3.19%)

IMBBY

Imperial Brands

$0.00

(0.00%)

PM

Philip Morris

$73.01

-1.89 (-2.52%)

REGI

Renewable Energy

$15.90

0.57 (3.72%)

PSX

Phillips 66

$102.77

0.66 (0.65%)

MPC

Marathon Petroleum

$53.29

0.1 (0.19%)

VLO

Valero

$85.53

1.84 (2.20%)

EVA

Enviva

$31.21

0.06 (0.19%)

AMTX

Aemetis

$1.00

0.14 (16.28%)

PEIX

Pacific Ethanol

$0.78

0.0322 (4.29%)

GPP

Green Plains Partners

$13.18

0.17 (1.31%)

DK

Delek US

$35.91

-0.6 (-1.64%)

HFC

HollyFrontier

$51.41

0.71 (1.40%)

TSO

Tesoro

$0.00

(0.00%)

WNR

Western Refining

$0.00

(0.00%)

T

AT&T

$37.90

-0.46 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 23

    Oct

  • 24

    Oct

  • 31

    Oct

  • 12

    Nov

GLD

SPDR Gold Shares

$140.19

-1.14 (-0.81%)

17:58
09/13/19
09/13
17:58
09/13/19
17:58
Hot Stocks
SPDR Gold Shares holdings fall to 874.51MT from 880.37MT »

This is the second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBVT

DBV Technologies

$10.22

0.595 (6.18%)

, AIMT

Aimmune

$24.66

(0.00%)

17:57
09/13/19
09/13
17:57
09/13/19
17:57
Hot Stocks
Breaking Hot Stocks news story on DBV Technologies, Aimmune »

DBV Technologies falls 2%…

DBVT

DBV Technologies

$10.22

0.595 (6.18%)

AIMT

Aimmune

$24.66

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

AIMT

Aimmune

$24.66

(0.00%)

17:55
09/13/19
09/13
17:55
09/13/19
17:55
Hot Stocks
FDA committee votes to support use of Aimmune's Palforzia for peanut allergy »

Aimmune Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

ZAYO

Zayo Group

$33.82

-0.05 (-0.15%)

17:39
09/13/19
09/13
17:39
09/13/19
17:39
Hot Stocks
Zayo Group CEO sells 1M common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

T

AT&T

$37.90

-0.46 (-1.20%)

, MO

Altria Group

$42.01

-0.77 (-1.80%)

17:38
09/13/19
09/13
17:38
09/13/19
17:38
Periodicals
CNN to longer run Juul ads, Daily Beast reports »

AT&T's (T) CNN…

T

AT&T

$37.90

-0.46 (-1.20%)

MO

Altria Group

$42.01

-0.77 (-1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

BAS

Basic Energy

$1.87

-0.08 (-4.10%)

17:34
09/13/19
09/13
17:34
09/13/19
17:34
Hot Stocks
Basic Energy CEO T.M. Patterson to leave company »

Basic Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

XBIO

Xenetic

$1.61

-0.04 (-2.42%)

17:28
09/13/19
09/13
17:28
09/13/19
17:28
Syndicate
Breaking Syndicate news story on Xenetic »

Xenetic files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$218.71

-4.4 (-1.97%)

, DIS

Disney

$138.00

0.44 (0.32%)

17:22
09/13/19
09/13
17:22
09/13/19
17:22
Hot Stocks
Disney CEO Bob Iger resigns from Apple board of directors »

In a regulatory filing,…

AAPL

Apple

$218.71

-4.4 (-1.97%)

DIS

Disney

$138.00

0.44 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

PHG

Philips

$47.79

0.19 (0.40%)

17:21
09/13/19
09/13
17:21
09/13/19
17:21
Hot Stocks
Philips awarded maximum $400M Defense Logistics Agency contract »

Philips has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBSE

NeuBase Therapeutics

$5.70

-0.04 (-0.70%)

17:20
09/13/19
09/13
17:20
09/13/19
17:20
Syndicate
Breaking Syndicate news story on NeuBase Therapeutics »

NeuBase Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

KDMN

Kadmon

$2.80

-0.015 (-0.53%)

17:18
09/13/19
09/13
17:18
09/13/19
17:18
Syndicate
Breaking Syndicate news story on Kadmon »

Kadmon files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KDMN

Kadmon

$2.80

-0.015 (-0.53%)

17:18
09/13/19
09/13
17:18
09/13/19
17:18
Syndicate
Breaking Syndicate news story on Kadmon »

Kadmon files $200M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$198.82

1.22 (0.62%)

17:17
09/13/19
09/13
17:17
09/13/19
17:17
Hot Stocks
Raytheon awarded $427.3M Army procurement contract »

Raytheon was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.